Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|May 3, 2021
CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor MicroenvironmentSara Santagata, Caterina Ieranò, Anna Maria Trotta, et al.
Cancer Treatment Reviews|December 11, 2017
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulationRobert L Ferris, Heinz-Josef Lenz, Anna Maria Trotta, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|January 30, 2014
Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studiesSusan Costantini, Raffaele Raucci, Giovanni Colonna, et al.
International Journal of Molecular Sciences|June 2, 2015
Conformational ensembles explored dynamically from disordered peptides targeting chemokine receptor CXCR4Marian Vincenzi, Susan Costantini, Stefania Scala, et al.
Journal of Translational Medicine|November 23, 2012
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcomeRosa Calemma, Alessandro Ottaiano, Anna Maria Trotta, et al.
Oncotarget|April 1, 2015
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patientsMaria Napolitano, Crescenzo D'Alterio, Eleonora Cardone, et al.
Journal of Medicinal Chemistry|March 10, 2018
Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer CellsDiego Brancaccio, Donatella Diana, Salvatore Di Maro, et al.
Cellular & Molecular Immunology|November 4, 2014
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does notMaria Neve Polimeno, Caterina Ierano, Crescenzo D'Alterio, et al.
Cancer Immunology Research|January 29, 2016
Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment EfficacyAnna Maria Trotta, Alessandro Ottaiano, Carmela Romano, et al.
Plos One|December 19, 2024
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cellsDaniela Russo, Anna Spina, Luigi Portella, et al.
Pageof 4